NASDAQ:KTOV - KITOV PHARMA LT/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.01 +0.01 (+1.00 %)
(As of 05/21/2019 03:10 PM ET)
Previous Close$0.9979
Today's Range$0.97 - $1.05
52-Week Range$0.56 - $3.81
Volume115,052 shs
Average Volume1.73 million shs
Market Capitalization$15.92 million
P/E Ratio2.59
Dividend YieldN/A
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing NT219, a small molecule that targets two pathways involved in cancer drug resistance. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.

Receive KTOV News and Ratings via Email

Sign-up to receive the latest news and ratings for KTOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KTOV



Sales & Book Value

Annual Sales$1 million
Cash Flow$0.3471 per share
Book Value$0.70 per share



Market Cap$15.92 million
Next Earnings DateN/A
OptionableNot Optionable

KITOV PHARMA LT/S (NASDAQ:KTOV) Frequently Asked Questions

What is KITOV PHARMA LT/S's stock symbol?

KITOV PHARMA LT/S trades on the NASDAQ under the ticker symbol "KTOV."

What price target have analysts set for KTOV?

1 Wall Street analysts have issued twelve-month target prices for KITOV PHARMA LT/S's stock. Their predictions range from $12.50 to $12.50. On average, they expect KITOV PHARMA LT/S's share price to reach $12.50 in the next year. This suggests a possible upside of 1,137.5% from the stock's current price. View Analyst Price Targets for KITOV PHARMA LT/S.

What is the consensus analysts' recommendation for KITOV PHARMA LT/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KITOV PHARMA LT/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for KITOV PHARMA LT/S.

Has KITOV PHARMA LT/S been receiving favorable news coverage?

News headlines about KTOV stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. KITOV PHARMA LT/S earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of KITOV PHARMA LT/S's key competitors?

What other stocks do shareholders of KITOV PHARMA LT/S own?

Who are KITOV PHARMA LT/S's key executives?

KITOV PHARMA LT/S's management team includes the folowing people:
  • Dr. John Paul Waymack, Founder, Chairman & Chief Medical Officer (Age 67)
  • Mr. Isaac Israel, CEO & Director (Age 41)
  • Dr. Hadas Reuveni, Founder & CTO of TyrNovo (Age 52)
  • Mr. Simcha Rock CPA, M.B.A., CPA, MBA, Strategic Advisor & Director (Age 69)
  • Dr. Gil Ben-Menachem M.B.A., MSc, MBA, Ph.D., VP of Bus. Devel. & Director (Age 52)


(KTOV) raised $13 million in an IPO on Friday, November 20th 2015. The company issued 3,200,000 shares at a price of $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar served as the underwriters for the IPO.

Who are KITOV PHARMA LT/S's major shareholders?

KITOV PHARMA LT/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.25%) and Morgan Stanley (0.21%).

Which major investors are buying KITOV PHARMA LT/S stock?

KTOV stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley and Virtu Financial LLC.

How do I buy shares of KITOV PHARMA LT/S?

Shares of KTOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KITOV PHARMA LT/S's stock price today?

One share of KTOV stock can currently be purchased for approximately $1.0101.

How big of a company is KITOV PHARMA LT/S?

KITOV PHARMA LT/S has a market capitalization of $15.92 million and generates $1 million in revenue each year. The company earns $-5,200,000.00 in net income (profit) each year or $0.39 on an earnings per share basis. KITOV PHARMA LT/S employs 10 workers across the globe.

What is KITOV PHARMA LT/S's official website?

The official website for KITOV PHARMA LT/S is

How can I contact KITOV PHARMA LT/S?

KITOV PHARMA LT/S's mailing address is One Azrieli Center Round Tower 132 Menachem Begin Road, Tel Aviv L3, 6701101. The company can be reached via phone at 972-3933-3121 or via email at [email protected]

MarketBeat Community Rating for KITOV PHARMA LT/S (NASDAQ KTOV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  245
MarketBeat's community ratings are surveys of what our community members think about KITOV PHARMA LT/S and other stocks. Vote "Outperform" if you believe KTOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KTOV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by Staff

Featured Article: What is an SEC Filing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel